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Abstract: Background: Sudden cardiac arrest is a major global health concern, and survival of patients
with ischemia–reperfusion injury is a leading cause of myocardial dysfunction. The mechanism
of this phenomenon is not well understood because of the complex pathophysiological nature of
the disease. Aim of the study was to investigate the cardioprotective role of fingolimod in an
in vivo model of cardiac arrest and resuscitation. Methods: In this study, an in vivo rat model of
cardiac arrest using extracorporeal membrane oxygenation resuscitation monitored by invasive
hemodynamic measurement was developed. At the beginning of extracorporeal life support (ECLS),
animals were randomly treated with fingolimod (Group A, n = 30) or saline (Group B, n = 30).
Half of the animals in each group (Group A1 and B1, n = 15 each) were sacrificed after 1 h, and the
remaining animals (Group A2 and B2) after 24 h of reperfusion. Blood and myocardial tissues were
collected for analysis of cardiac features, inflammatory biomarkers, and cell signaling pathways.
Results: Treatment with fingolimod resulted in activation of survival pathways resulting into reduced
inflammation, myocardial oxidative stress and apoptosis of cardiomyocytes. This led to significant
improvement in systolic and diastolic functions of the left ventricle and improved contractility index.
Conclusions: Sphingosine1phosphate receptor activation with fingolimod improved cardiac function
after cardiac arrest supported with ECLS. Present study findings strongly support a cardioprotective
role of fingolimod through sphingosine-1-phosphate receptor activation during reperfusion after
circulatory arrest.
Keywords: fingolimod; cardioprotection; cardiac arrest; extracorporeal life support; resuscitation
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1. Introduction
Despite rapid advancements in the field of medicine worldwide, sudden cardiac arrest is
still a common cause of death in patients with hereditary and ischemic heart diseases [1,2].
The post-resuscitation mortality rate in such patients is about 50% [3]. Both cardiac arrests and
cardiopulmonary resuscitation are associated with global myocardial ischemia–reperfusion injury
which leads to myocardial dysfunction, resulting in poor prognosis and adverse outcomes [4]. Currently,
extracorporeal life support (ECLS) is an effective way of treating cardiogenic shock or cardiac arrest
because of its great potential to provide swift circulatory support via peripheral vascular access [5].
Sphingosine 1-phosphate (S1P) is known to play a role in cellular changes such as differentiation,
proliferation, migration, contraction, and survival [6–11]. Sphingosine 1-phosphate sphingolipid
derivatives are known to have anti-inflammatory, anti-apoptotic, and anti-oxidant activities, and have
significant roles in the cardiovascular system [12,13]. Sphingosine 1-phosphate increases the survival
of cardiomyocytes during episodes of hypoxia [14]. Some in vitro studies have shown associated
decreases in the size of the infarcted area in isolated hearts in both ex vivo and in vivo models [15–17].
The role of sphingosine 1-phosphate in cytoprotection through the activation of survival pathways
is under intense investigation. Pharmacological post-conditioning with sphingosine 1-phosphate
activation has been investigated for potential application after resuscitation in in vitro and in vivo
studies [18]. Fingolimod, a sphingosine 1-phosphate receptor agonist, has not been thoroughly
investigated in its role as a pharmacological cardioprotective agent for post-cardiac arrest resuscitation
care. The present study hypothesis was that fingolimod plays a cardioprotective role in global
ischemia–reperfusion injury related to sudden cardiac arrest. Therefore, the aim of this study was to
assess the cardioprotective effect of fingolimod through sphingosine 1-phosphate receptor activation
after resuscitation from cardiac arrest during ECLS in a rat model. For a better understanding of the
cardioprotective mechanism involved, we investigated functional hemodynamic parameters, some
of the inflammatory mediators and cardiac biomarkers, Akt1/2 and Erk1/2 pathways, nitro-oxidative
stress, apoptosis, and myocardial fibrosis.
2. Methods
2.1. Study Design and Setting
This study was conducted in the Division of Cardiac Surgery and Translational Surgery Lab,
University of Verona Medical School, Verona, Italy.
2.2. Animals
Sprague–Dawley rats (300–350 g) were obtained from Harlan Laboratories (Udine, Italy).
Rats placed at a density of 2 per cage received the standard diet (rat chow) and had free access
to water and they were maintained on a 12 h light/dark cycle at 21 ◦C. The study was approved
by The Ethical Committee of the University of Verona and the National Animal Welfare Committee
(BB-CCH#13371, 16/03/2016).
2.3. Experimental Design
Rats were orotracheally intubated with an atraumatic tube constituting a venous cannula of 14 G.
The rats were then ventilated with a mechanical respirator for rodents (Inhale, Harvard Apparatus,
Holliston, MA, USA) with a mixture of oxygen and anesthetic Sevorane 2% (Abbott Laboratories,
Sittingbourne, UK), which guaranteed anesthesia for the duration of the procedure, with a fraction
of inspired oxygen (FiO2) of 90%, a tidal volume of 10 mL/kg; a frequency of 70 breaths per minute
of vecuronium bromide (0.1 mg/kg body weight) was administered to obtain complete muscular
relaxation and repeated if needed; 1 mg Ketoprofene was administered subcutaneously for analgesia.
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Rats were placed in supine position. Thoracic area, ventral surface of the neck, and the hind legs
were shaved and skin was disinfected with povidone iodine. A thermocouple microprobe was inserted
into the rectum in order to monitor animal temperature during experiment.
Right femoral artery was isolated and a miniaturized catheter with a diameter of 2 Fr (model
SPR 838, Millar Instruments, Houston, TX, USA) was inserted for continuous monitoring of systemic
blood pressure. Subsequently, the femoral vein was cannulated with a 24 G cannula followed by
administration of 500 UI/kg heparin to ensure patency and readiness for ECLS.
Access to heart was achieved via a median sternotomy, and the chest was kept open with a
retractor. A venous cannula (a modified four-hole catheter, caliber of 5 Fr) was advanced through the
external jugular vein to the right atrium. The left common carotid artery was cannulated with a 24 G
catheter which was advanced to the aortic arch and connected to the line of arterial perfusion circuit.
The extracorporeal circulation circuit constituted a roller pump (Stockert SIII, Sorin, Germany),
a hollow fiber oxygenator (Sorin, Mirandola, Italy), and a venous reservoir connected to a vacuum to
facilitate venous drainage. All were connected by plastic tubing with inner diameters of 1.6 mm. The
total fill volume of the extracorporeal circuit including the oxygenator was 6 mL and constituted colloid
solution and lactated Ringer’s. The exchange surface of the gas was 450 cm2 and the heat exchange
surface area was 15.8 cm2. Once venous and arterial accesses were in place, cardiac arrest was induced
by ventricular fibrillation using a fibrillator with a current of 3.5 mA at 60 Hz released at the level of
right ventricular epicardial region. During cardiac arrest, the ventilation was stopped. After 10 min of
cardiac and respiratory arrest, ECLS was started and maintained with a flow rate of 80–100mL/kg/min
and a mean arterial pressure range of 70–90 mmHg. During ECLS, internal temperature was kept at
35–36◦C in both the groups. After 10–15 min of ECLS, spontaneous circulation was restored, ECLS was
maintained for 60 min, and then the rats were weaned from extracorporeal circulation.
At the initiation of ECLS, rats were randomly categorized into two groups (Groups A and B).
Group A was treated with normal saline, while in animals of Group B, fingolimod was administered at
a dose of 1 mg/kg through femoral vein.
In Group A1 and B1, after 1 h of reperfusion, hemodynamic measurements were collected through
the Millar catheter inserted into the left ventricle, and myocardial tissue was collected to analyze
high energy phosphates and other biomarkers. In the Groups A2 and B2, reperfusion was continued
up to 24 h. After 24 h of reperfusion, hemodynamics was measured similarly at 1 h and blood and
myocardial tissue were collected for further analysis of inflammation, apoptosis and, oxidative stress.
A schematic diagram illustrates the various steps of the experiment (Figure 1).
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2.4. Hemodynamic Analysis
Determination of hemodynamic parameters was carried out at baseline and after ECLS weaning
using a pressure–volume (P-V) conductance catheter with a 2 Fr microtip (SPR-838, Millar Instruments,
Houston, TX, USA) which was inserted into the right carotid artery, extending into the left ventricle.
Recording of signals was done at a sampling rate of 1000 samples/s using a P-V conductance system
(MPVS-400, Millar Instruments). These were stored and displayed on a personal computer by the
PowerLab Chart 5 Software System (AD Instruments, Colorado Springs, CO, USA). Hemodynamic
parameters were determined by recording left ventricular end systolic and diastolic pressures along
with contractility index (dp/dt min and dp/dt max).
2.5. Analysis of Serum Inflammatory Mediators and Biomarkers
After the ischemia and reperfusion phase, blood was collected and placed at room temperature
for 30 min. Serum was collected and the concentrations of serum inflammatory mediators TNF-α,
IL-6, ICAM-1, and IL-1β were determined using ELISA-based kits obtained from Thermo Scientific
(Rockford, IL, USA). The serum levels of CK-MB and cardiac Troponin-I were measured using CK-MB
and Cardiac Troponin-I Assay Kits (Sigma-Aldrich, Gillingham, UK).
2.6. Quantification of Oxidative Stress
For determination of malondialdehyde (MDA) and reactive oxygen species (ROS) in myocardial
tissue, a commercially available method was adopted (Thermo fisher, Waltham, MA, USA); tissue pieces
were proc ssed at 37 ◦C, 5% CO2 95% air atmosphere for 60 min according to the manufacturer’s
instructi ns. The m ocardial tissue was incubated at 37 ◦C for 30 min in PBS (137 mM NaCl, 2.7 mM
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KCl, 9.8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.3). Absorbance at 490 nm was measured with a
microplate reader (EL × 800; Bio-Tek, Winooski, VT, USA).
For determination of nitrogen reactive oxygen species (peroxynitrites), the nitrosylation of cardiac
proteins was measured using an antibody against nitrotyrosine, as described in the following section.
2.7. Immunoblotting Analysis
For immunoblotting assays, rabbit antibodies for non-phosphospecific Akt1/2 and ERK1/2 goat
anti-rabbit IgG conjugated with horseradish peroxidase (HRP) were purchased from Abcam (Cambridge,
UK), while rabbit anti-phosphorylated Akt1/2 and ERK1/2 antibodies were purchased from (Cell
Signaling, Beverly, MA, USA). The remaining reagents were purchased from (Sigma Chemical, St. Louis,
MO, USA).
Homogenization of heart tissue was carried out in a buffer solution containing 1% Triton 100-X and
phosphatase and protease inhibitors cocktail (Sigma Chemical, St. Louis, MO, USA) as described by
Giani et al. [19]. After centrifugation of the homogenate at 16,000 rpm for 15 min at 4 ◦C, the supernatant
was collected in separate aliquots. Protein concentration of the tissue extract was measured using the
BCA assay kit (Beyotime Institute of Biotechnology, Jiangsu, China). For analysis of phosphorylation
levels of Akt1/2 and ERK1/2, equal amounts of solubilized proteins (35µg) were denatured by boiling for
5 min at 100 ◦C in reducing buffer, and then resolved by SDS-PAGE. The protein was then transferred to
polyvinylidene difluoride (PVDF) membranes. PVDF membranes were pre-wetted with methanol and
distilled water prior to submersion in 30% methanol containing transfer buffer. After transfer of protein,
the membranes were incubated for 1 h in blocking solution that contained 5% FBS in TBS containing
0.1% Tween 20. After blocking, primary antibodies were diluted (1:1000) in blocking solution and
incubated over night at 4 ◦C with unphosphorylated and phosphospecific antibodies. Equal loading of
protein in the acrylamide gels was confirmed by reusing the PVDF membranes with antibody against
an anti-GADPH. Unbound primary antibody was washed extensively from the membranes with TBS-T
solution for 20 min. These membranes were then incubated with secondary antibodies conjugated
with HRP at a rate dilution of (1:10,000) and substrate of HRP chemiluminescence as a result of reaction
was measured through a Syngene Western blotting detection system. Protein band densities were
analyzed using ImageJ 1.37 software.
2.8. Immunohistochemical Staining
Heart tissue sections of 3 um thickness were placed on slides and heated to 60 ◦C for 1 h,
and then rehydrated using graded concentration ethanol. Antigen retrieval was carried out using
appropriate buffer and the procedure explained previously [12]. Endogenous peroxidase activity was
blocked by incubation of tissue section, carried out at 4 ◦C overnight. This was followed by washing
of primary antibodies and incubation with biotin-conjugated secondary antibody for 30 min and
di-aminobenzidine and hydrogen peroxide chromogen substrate (Dako Corp., Carpinteria, CA, USA).
Counter staining of all slides was done with hematoxylin. Rabbit IgG in place of primary antibody was
used as a negative control. Slides were examined using a Nikon E400 microscope (Nikon Instrument
Group, Melville, NY, USA).
2.9. High-Energy Phosphates
High-performance liquid chromatography was used to quantify adenosine monophosphate
(AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), and phosphocreatine (PCr),
as elaborated in a previous publication [20]. Calculation of energy charge (EC) was done according to
the following formula: EC = (ATP + 1/2 ADP)/(ATP + ADP + AMP) [21].
2.10. TUNEL Assay
Heart tissue was deparaffinized with 100% xylene following serial concentrations of ethanol.
Apoptotic cells were stained and the Click-it plus terminal deoxynucleotidyl transferase dUTP nick end
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labeling (TUNEL) assay was used for the in situ apoptosis assay. (Molecular Probes Life Technology,
Thermo Scientific). Hoechst 33342 staining solution was used for examining nuclei [12].
2.11. Histology and Interstitial Fibrosis Determination
Three micron sections obtained from the paraffin-embedded left ventricular myocardial tissue
were stained with hematoxylin–eosin staining, and histological measurements were expressed as
a diameter (µm) of cardiomyocyte. Masson’s trichrome was used to evaluate cardiac fibrosis as
mentioned in previously [22].
2.12. Statistical Analysis
All measurements and results are presented as mean ± SD. Control and treatment groups
were compared using Student’s t-test or Mann–Whitney U nonparametric test. Analyses were
performed using SPSS software version 21 (SPSS Inc., Chicago, IL, USA) and a p-value < 0.05
was considered significant.
3. Results
3.1. Left Ventricular Function
Regarding baseline hemodynamic parameters, no significant difference was seen between control
and treatment groups (Table 1). All rats were subjected global ischemia through CA following
fingolimod treatment in Groups B1 and B2 and saline treatment in Group A1 and A2 (n = 15 in each
group). Hemodynamic parameter measurements were done to evaluate LV performance using the
Millar catheter system.
Table 1. Comparison of baseline characteristics among different groups.
Baseline Group A1 Group B1 p Value Group A2 Group B2 p-Value
HR (beats/min) 281 ± 16 278 ± 21 Ns 309 ± 29 295 ± 24 ns
MAP (mmHg) 137 ± 16 132 ± 18 Ns 112 ± 14 116 ± 16 ns
CO (mL/min) 42 ± 3.5 45 ± 4.2 Ns 44 ± 3 47 ± 5.2 ns
The LV end systolic pressure (LVESP) elevated significantly after CA and resuscitation in Group
B2 as compared to Group A2 (p ≤ 0.05) (Figure 2A). No difference between Groups A1 and B1 was
observed (p > 0.05). The LV end diastolic pressure (LVEDP) measurements showed a reduction in
Groups B1 and B2 vs. Groups A1 and A2 (p ≤ 0.05) respectively (Figure 2B). The minimal pressure
relaxation rate (dP/dt min) was also found to be improved in Groups B and D as compared to Group
A1 and Group A2 (p ≤ 0.05) (Figure 2C). Ventricular systolic performance dp/dt max after CA and
reperfusion was increased in Group B2 vs. Group A2 (p ≤ 0.05) (Figure 2D).
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Figure 2. He odyna ic ar t 4 of reperfusion. Effects of
FTY720 on left ventricular function in the rats with a CA-reperfusion-i duced injury. Following 10 min
of CA, treatment was administered a the star of reperfusion. (A) Effects of FTY720 on LVESP. (B) Effects
of FTY720 n LVEDP. (C) Effects of FTY720 on LV dp/dt min. (D) Effects o FTY720 on LV dP/dt
max. LVESP and LVEDP were measured using a multichannel physiological recorder. L dP/dt
max and min are expres ed as /sec. s g. LV dP/dt
max: t e i positive left ventricular pressure development; LV dP/dt max: the rate
of maximum negative left ventricular pressure development; LVESP: left ventricular end-systolic
pres ure; LVEDP: left ventricular end- iastolic pressure. Values are express d as means ± SD. * p < 0.05,
** p < 0.001.
3.2. Serum Levels of Inflammatory ediators and Cardiac arkers
In comparison ith the baseline, CA-related I/R injury was marked by elevation in the levels
of cytokines, mainly TNF-α, IL-1β, IL-6, and ICAM-1. All these cytokines were increased in serum
in response to ischemia and reperfusio . In the present study, these mediators were measured in
CA–reperfusion-related I/R injury. Although, ICAM-1 was indepe dently increased in response to I/R,
in CA-related-ischemia–reperfusion injury, elevation was observed. Compared to baseline serum levels
of TNF-α, IL-6, IL-1β, and ICAM-1, serum levels were significantly increased in CA–reperfusion gr up
(p ≤ 0.001). On administration of fingolimod (1 g/kg) there was att nu tion i serum lev ls of TNF-α,
IL-6, 1L 1β, and ICAM-1 compared t the con rol group (p ≤ 0.05), p ≤ 0.05, p 0.05, and p ≤ 0.001)
respectively), as shown in Figure 3A–D.
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Figure 3. Myocardial production of TNF-α, IL-6, ICAM-1, and IL-1β after 10 min CA and 24 h of
reperfusion. (A) CA model without fingolimod treatment showed high expression of TNF-α compared
to the model with fingolimod treatment. (B) CA-reperfusion induced significantly heightened IL-6 after
24 h of reperfusion compared with the fingolimod-treated and baseline groups. (C) FTY720-treated
group showed a remarkably reduced production of ICAM-1 as compared to control. (D) Production
of 1L-1β was higher in control vs. FTY720-treated group in CA–reperfusion group. (E,F) Serum
levels of creatinine kinase-MB (CK-MB) and cardiac Troponin I (cTnI) in the serum of rats in the
baseline, CA-reperfusion, and CA-reperfusion + fingolimod group (1 mg/kg) groups. Each bar height
represents the mean ± SD (each group n = 15). (## p ≤ 0.01 vs. baseline. * p ≤ 0.05 and ** p ≤ 0.01 vs.
CA control group).
Cardiac markers of cardiomyocytes injury, the serum levels of CK-MB and cTnI, were found to be
22 ± 9.3 and 5.35 ± 0.60 U/g protein in the baseline-operated group. These were significantly increased
in the CA–reperfusion group to 128.8 ± 10.9 and 21.72 ± 0.99 U/g protein, respectively. After treatment
with fingolimod, the CK-MB and cTnI levels were significantly decreased (Figure 3E,F).
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3.3. Effect of Fingolimod on Nitro-Oxidative Stress
Nitrative stress plays an important role in myocardial tissue injury under ischemia–reperfusion.
Excessive NO production from NOS and the reaction product between NO and peroxynitrite superoxide
has been observed to activate apoptotic signaling pathways, leading to apoptotic cell death. To examine
whether fingolimod reduced myocardial nitrative stress caused by CA-related ischemia–reperfusion,
and thus attenuation in myocardial apoptosis, we determined peroxynitrite expression. As illustrated
in Figure 4 A, B, fingolimod markedly downregulated peroxynitrite expression. This was shown by
indicates decreased production of nitrotyrosine.
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Figure 4. Myocardial nitrotyrosine staining of (A) FTY720-treated group (n = 15 each) and (B) Control
group (n = 15 each), Rats were subjected to 10 min CA followed by 24 h reperfusion. At the end of the
experiment, th heart was removed, a d nitro yrosine localization was determined. Magnification 20×,
scale bar 100 µm. (C) Comparison of oxidative stress in fingolimod-treated and control group.
ROS: reactive oxygen species, CA: cardiac arrest, FTY720: fingolimod; Carr. unit: Carratelli unit.
(** p ≤ 0.001, * p ≤ 0.05).
To examine whether fingolimod regulates free radical production in ischemia–reperfusion,
we examined free oxygen radicals and aldehydes (lipid peroxidation derivatives) in the frozen samples
of myocardial tissue. In the CA control group, reactive oxygen species levels were found to be higher as
compared to those in the CA–fingolimod-treated group, as determined by chromatography and mass
spectrometry. Overall, our results showed that the fingolimod treatment in CA decreases oxidative
stress (Figure 4C).
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3.4. Bcl-2 and Bax Signaling Pathways
After 10 min of CA and 24 h of reperfusion, myocardial tissue was excised for immunohistological
staining to measure the expression levels of anti-apoptotic (Bcl-2) and pro-apoptotic (Bax) proteins.
In the fingolimod-treated group (Group B2), Bcl-2 expression was significantly increased versus the
CA control group (Group A2), while expression of Bax was down-regulated in Group B2 as compared
to Group A2 (p ≤ 0.05). This indicates that fingolimod during CA decreases apoptosis by upregulating
Bcl-2 and downregulating Bax proteins (Figure 5A–D).
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Figure 5. Myocardial tissue expression levels of Bax after 10 min of CA and 24 h reperfusion.
The protein xpression lev ls of Bcl-2 and BA ter ined by i munohistochemistry, (A) BAX
expr ssion in CA control group, (B) Bax expres io i TY720-treated group (control vs. treated
p ≤ 0.05). (C) Bcl-2 expression in control C group and ( ) Bcl-2 expression in FTY720-treated group
(control vs. treated (p ≤ 0.05)). Magnification 20×, scale bar 100 µm. Representative western blot and
relative density ratio of the phosphorylated (p) form of Akt1/2 (D) ERK1/2; (E) samples of left ventricle
at the end of 24 h reperfusion. Relative densities showed that fingolimod activates phosphorylation of
these proteins. Values presented are means ± SD; (n =15 samples/group). (* p ≤ 0.05, ** p ≤ 0.001).
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3.5. Effect of Fingolimod on Erk1/2 and Akt1/2 Signaling Pathways
Pro-survival signaling pathways were measured in the myocardial tissue. The Akt/PI3 kinase
pathway is a signaling pathway important for survival. We measured the phosphorylation level of
Akt1/2 in Groups A2 and B2 in the myocardial tissue. As shown in Figure 3E, phosphorylation levels
of Akt1/2 were higher compared to the control group (p ≤ 0.05). ERK1/2 phosphorylation was also
analyzed by western blot in rat myocardial samples. As shown in Figure 3F, phosphorylation level of
ERK1/2 was found to be increased in Group B2 compared to Group A2 (p ≤ 0.05) (Figure 3E,F).
3.6. High-Energy Phosphates
In the model of CA and resuscitation, measurement of high energy phosphates revealed
superior preservation in myocardium following fingolimod treatment (Figure 6). Phosphocreatine was
significantly higher in the fingolimod-treated group of animals compared with the control group tissue
(p ≤ 0.001), whereas ATP was significantly increased after both the 1 h and 24 h of reperfusion in treated
group compared to the control group (p ≤ 0.05). Energy charge was significantly elevated after 1 h
of reperfusion in the fingolimod-treated group as compared with the control group (0.85 ± 0.12 vs.
0.63 ± 0.15; p ≤ 0.05). Even after 24 h reperfusion, it remained significantly higher compared to the
control group (0.83 ± 0.13).
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Figure 6. High-energy phosphates in myocardial tissue of the LV in the fingolimod-treated groups
compared with the control group. (A) AMP, ADP, and ATP levels at 1 h and 24 h of reperfusion;
(B) changes in phosphocreatine, (* p ≤ 0.05, ** p ≤ 0.001). AMP: adenosine monophosphate;
ADP, adenosine diphosphate; ATP, adenosine triphosphate.
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3.7. Effect of Fingolimod on Apoptosis
The TUNEL assay is a standard way to assess apoptosis. Group A2 showed extensive apoptosis.
However, S1P receptor activation by fingolimod presented a significant attenuation of TUNEL-positive
nuclei in myocardial tissue following cardiac arrest and reperfusion. This indicates that fingolimod
exerts an anti-apoptotic role in I/R related to CA (Figure 7).
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Figure 7. Representative photomicrographs of immunofluorescent staining for TUNEL-positive
nuclei in the baseline, I/R control, and I/R–fingolimod groups. (A,D,G) DAPI in myocardial tissue,
(B,E,H) positive TUNEL signals, and (C,F,I) merged images. TUNEL-positive myocytes were much
lower in numbers frequently in control CA group than in CA-FTY720 group. Original magnification
20×. Scale bar 100 µm.
3.8. Effect of Fingolimod on ollage eposition and Neutrophil Infiltration
Interstitial collagen deposition was easured by collagen volume fraction (CVF) to evaluate
myocardial fibrosis after VF-induced CA and reperfusion for 24 h. The interstitial collagen deposition
in the late phase of reperfusion was significantly reduced in the fingolimod-treated group (Figure 8A,B).
To calculate CVF, we measured the collagen staining expression (blue) in Masson’s trichrome-stained
images. In CA-I/R group, we observed interstitial edema and structural disarray, including neutrophil
infiltration. However, pre-ischemia fingolimod treatment reduced morphological changes and
neutrophil infiltration remarkably. The difference between control and treated group was statistically
significant (p ≤ 0.05) (Figure 8C,D).
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Figure 8. ( ,B) Representative photomicrograph showing the Masson’s tricho e stain, illustrating
collagen deposition in CA-induced ischemia–reperfusion myocardium after 24 h. FTY720 was attenuated
following CA myocardial interstitial collagen deposition. The viable myocardium is stained bright
red. Collagen fibers are stained bright blue. (C,D) Representative photomicrograph showing the
histopathological changes in CA-induced ischemia–reperfusion: (C) cardiac section showing interstitial
edema and neutrophil infiltration in control and (D) heart tissue section showing mild necrosis and
band contractions in fingolimod-treated group (20 × magnification).
4. Discussion
Sudden cardiac arrest is a major health concern worldwide, and is the most frequent cause
of death. Various cardioprotective strategies to prevent acute global ischemia–reperfusion injury
has been tested. In the last two decades, multiple experimental studies have been carried out to
identify the cardioprotective roles of various substances including volatile anesthetic agents [23–25],
sodium hydrogen exchange inhibitors [26], statins [27], pharmacological preconditioning agents [28],
and anti-inflammatory drugs [29]. A vast majority of these preclinical strategies could not work
in actual clinical settings. In the present study, administration of fingolimod resulted in decreased
inflammation, oxidative stress, and preservation of high energy phosphates in cardiomyocytes,
which may contribute to enhanced cardioprotection. Our results showed inhibition of pro-apoptotic
and activation of anti-apoptotic proteins, and reduction in oxidative and nitrative stress. Our results
agree with the earlier findings that the phosphorylation of Akt1/2 and Erk1/2 is important for cell
survival pathways [30–32].
Several studies have suggested a cardioprotective role of fingolimod through activation of survival
pathways in rodent models [15,16]. One such study used S1P receptor knock-out mice showed a high
level of myocardial damage as compared to wild-type mice [33]. In another study, mice lacking in
sphingosine kinases were found to have greater size of infarction as compared to control mice when
subjected to cardiac arrest. Studies have shown that not only the activation of S1P receptors, but also
the metabolism of S1P is important in pre- and post-conditioning cardioprotective mechanisms [34,35].
Ischemia–reperfusion injury can be caused by different mechanisms and pathways. Activation of
apoptotic pathways, complement system activation, increased inflammation, and oxidative stress
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can cause myocardial injury following ischemia–reperfusion [36]. Fingolimod shows potential to
deal with most of the above mentioned myocardial damaging mechanisms to prevent I/R injury.
Reperfusion after transient ischemia in myocardium leads to apoptosis in cardiomyocytes and cardiac
dysfunction [37,38]. TUNEL-positive nuclei staining, i.e., the standard method to measure level of
apoptosis, was used in this study. Our investigation was consistent with previous studies [12] showing
that rats treated with fingolimod expressed a lower frequency of TUNEL-positive nuclei after 24 h of
reperfusion, supporting the cardioprotective role of fingolimod by activating anti-apoptotic cascade.
S1P receptor agonists have important roles in immune suppression [39]. A porcine model
of I/R [17] and a spontaneous obstructive coronary atherosclerosis murine model [40] tested for
immunosuppression, showed reduction in infarct size and mortality in the fingolimod-treated group.
In the present study, a significantly lower concentration of pro-inflammatory cytokines was found in
blood and tissues subjected to inflammation, a finding concordant with the previous data [40].
ICAM-1, IL-6, IL-1β, and TNF-α contribute to develop inflammatory mechanisms as
pro-inflammatory cytokines [41–43]. A correlation was found between the anti-inflammatory effect of
fingolimod on cardioprotection. I/R increased ICAM-1, IL-6, IL-1β, and TNF-α levels in the control
group, whereas fingolimod treatment decreased the concentrations of these cytokines. Therefore, the
suppression of inflammatory cytokines by fingolimod treatment may protect the myocardium from I/R
injury caused by pro-inflammatory cytokines, as evident from the present study.
One of the main targets of this drug was to mitigate apoptosis in I/R. During I/R, molecular
signaling via RISK and SAFE pathway activation has been reported [16,44]. The RISK (Akt1/2, Erk1/2,
and GSK-3β) and SAFE (JAK and STAT3) pathways are main sources for mitigation of apoptosis by
preventing opening of the mitochondrial permeability transition pore [45–47]. Consistent with the
previous findings, activation of RISK and SAFE signaling pathways was observed following decreased
level of apoptosis in treated group compared to the control. The inhibition of pro-apoptotic proteins
Bax and enhanced immunoreaction for anti-apoptotic protein Bcl-2 was found after 10 min of CA and
24 h of reperfusion.
This study was not without limitations. Sudden cardiac arrest patients may have other
underlying pathologies and co-morbidities including diabetes, hypertension, and hyperlipidemia.
Our experimental model did not truly reflect those conditions; this could be the reason that many
studies on experimental models have failed to show the same beneficial effects in actual clinical practice.
However, in a recent study, we showed that the rat model, due to similarities in the SIP receptors
between rat and human heart, is a more appropriate model to study the beneficial effects of fingolimod
in clinical trials [13].
In our study, maximum reperfusion time was 24 h, and we did not study the effect of fingolimod in
late phase. Prolonged reperfusion could have provided more strong evidence of reduction in I/R injury.
The effect of fingolimod in structural remodeling can be studied only if there is prolonged reperfusion
time. However, due to complex surgical procedures, it was hard to achieve this in our model.
Furthermore, we administered only one dose before initiating ischemia in our model. There is a
possibility that multiple doses of fingolimod could offer better cardioprotection. Further studies need
to be conducted in order to check the efficacy of multiple doses.
Although fingolimod is generally considered safe and well tolerated, adverse effects of transient
bradycardia and atrioventricular block have been reported nonetheless. These adverse effects were
resolved spontaneously in majority of the cases. Moreover, it is recommended to use fingolimod in
hospital settings under strict monitoring so that the likelihood of these adverse effects can be minimized
using timely counter medication if required.
In spite of these limitations, we speculate that fingolimod has great potential to be used for
cardioprotection in cardiac arrest. On the basis of these findings, it can be suggested that sphingosine
1-phosphate receptor activation in patients with cardiac arrest could be most important for assessment
of the potential clinical efficacy of this cardioprotective agent.
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5. Conclusions
In conclusion, fingolimod plays important role in preservation of cardiac mechanical
functions, reduction in myocardial apoptosis, inflammation, and nitro-oxidative stress. The potential
cardioprotective mechanism is associated with activation of the reperfusion injury salvage kinase and
survivor activating factor enhancement pathways. Furthermore, hemodynamic parameters improved
in the late phase of reperfusion. The results of this study might be a potential source for translation
into clinical treatment.
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